Skip to main content

Table 2 oHSVs of genetic engineering and its clinical application

From: Oncolytic herpes simplex virus and immunotherapy

oHSV name

Genetic modification

Descrption

Clinical application

Dlsptk

TK−(UL23)

Internal deletion within UL23

Malignant human gliomas

hrR3

UL39

Insertion of LacZ (encodes β-galactosidase) in UL39

Pancreatic cancer; colon carcinoma; liver cancers

HSV1716

ICP34.5

Deletion in both copies of ICP34.5

Glioblastoma multiforme; anaplastic astrocytoma; oral squamous cell carcinoma

R3616

ICP34.5

Deletion of two copies of ICP34.5

Pancreatic cancer; colon carcinoma

G207

ICP34.5

Deletions of two copies of the ICP34.5; insertion of an Escherichia coli LacZ

Prostate adenocarcinoma; glioblastoma; hepatocellular carcinoma; colorectal cancer

R7020 (NV1020)

UL23, UL55, UL56, RL1, RL2, RS1

Deletion of UL23, as well as the region encoding UL55, UL56, and one copy of RL1, RL2, and RS1 (though not the RS1 promoter)

Pancreatic cancer; colon carcinoma; bladder cancer; pleural cancer

G47Δ

RL1, UL39, US11, US12

Deletion of the overlapping US11 promoter/US12 region, putting expression of the normally late US11 gene under the immediate early US12 promoter

Prostate adenocarcinoma; glioblastoma; rectal cancer; nasopharyngeal carcinoma; breast cancer

OncoVexGM-CSF

ICP34.5 and ICP47

Deletion of two copies of ICP34.5 gene and the viral ICP47 genes; insertion of GM-CSF

Breast cancer; head and neck cancer; gastrointestinal cancers; malignant melanoma

HF10

UL53, UL54, UL55, UL56

Spontaneous deletion of UL56 as well as duplication of UL53, UL54, and UL55

Breast cancer; malignant melanoma; pancreatic cancer

DM33

ICP34.5

Deletions of γ-34.5 and LAT gene

Human gliomas and glioma cell line